Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2012
04/26/2012US20120100155 Pharmaceutical agent
04/26/2012US20120100154 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
04/26/2012US20120100149 Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent
04/26/2012US20120100144 Biomarker and Treatment for Cancer
04/26/2012US20120100138 The use of inhibitors of bruton's tyrosine kinase (btk)
04/26/2012US20120100135 Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
04/26/2012US20120100124 Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer
04/26/2012US20120100123 Compositions and methods for the prevention of cardiovascular disease
04/26/2012US20120100122 Combination therapy
04/26/2012US20120100120 Performance enhancing composition and method of delivering nutrients
04/26/2012US20120100116 Neuron generation, regeneration and protection
04/26/2012US20120100107 In vivo transfer methods for wound healing
04/26/2012US20120100104 Antiviral Compounds And Uses Thereof
04/26/2012US20120100100 Cyclin dependent kinase inhibitors and methods of use
04/26/2012US20120100088 Apigenin-containing composition
04/26/2012US20120100084 Polymers based on arcrylic, methacrylic or ethacrylic amidoalkyl sulfonic acid or salts and carboxyalky acrylate, methacrylate or ethacrylate or oligomers of said carboxy compounds
04/26/2012US20120100081 Composition and Method for Treating Wounds
04/26/2012US20120100080 Econazole Composition and Methods of Treatment Therewith
04/26/2012US20120100077 Mixture of amphipathic molecules and method for modifying cell membranes by means of fusion
04/26/2012US20120100067 Solubilisation Method
04/26/2012US20120097160 Agglomerate formulations including active pharmaceutical agents with targeted particle sizes
04/26/2012DE202008018254U1 Kosmetische und pharmazeutische Anwendungen von N-Acetylhydroxyprolin Cosmetic and pharmaceutical applications of N-acetylhydroxyproline
04/26/2012DE102010049595A1 Chinazolinderivate Quinazoline derivatives
04/26/2012DE102010042833A1 Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung New Halogenalkoxychinazoline, their preparation and use
04/26/2012CA2852978A1 Methods for the prevention and/or treatment of memory impairment
04/26/2012CA2852904A1 Assays, methods and kits for predicting renal disease and personalized treatment strategies
04/26/2012CA2818662A1 Nucleic acid molecule inducing rna interference, and uses thereof
04/26/2012CA2816033A1 Cathepsin s inhibitor compounds
04/26/2012CA2815422A1 Antigen-specific, tolerance-inducing microparticles and uses thereof
04/26/2012CA2815353A1 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
04/26/2012CA2815350A1 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
04/26/2012CA2815321A1 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
04/26/2012CA2815299A1 Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose
04/26/2012CA2815212A1 Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
04/26/2012CA2815142A1 1-(heterocyclic carbonyl)-2-substituted pyrrolidines
04/26/2012CA2815131A1 Substituted 6-amino-nicotinamides as kcnq2/3 modulators
04/26/2012CA2815127A1 Quinoxaline derivatives
04/26/2012CA2815109A1 Cysteine and food intake
04/26/2012CA2815063A1 Processes for the preparation of rivaroxaban and intermediates thereof
04/26/2012CA2815055A1 Viral polymerase inhibitors
04/26/2012CA2815035A1 Carbonate derivatives for the treatment of cough
04/26/2012CA2815025A1 Chemosensory receptor ligand-based therapies
04/26/2012CA2815024A1 Chemosensory receptor ligand-based therapies
04/26/2012CA2814975A1 Topical gel composition
04/26/2012CA2814952A1 Brimonidine gel compositions and methods of use
04/26/2012CA2814840A1 Sustained-release formulation for injection
04/26/2012CA2814805A1 Ready to use ketorolac formulations
04/26/2012CA2814795A1 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
04/26/2012CA2814594A1 Tetrahydroquinoline derivatives used as ampk activators
04/26/2012CA2814581A1 Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
04/26/2012CA2814577A1 Use of storage stable viscous phospholipid depot to treat wounds
04/26/2012CA2814378A1 Antimicrobial polyether and polyol compounds
04/26/2012CA2814103A1 Pharmaceutical topical composition of mupirocin
04/26/2012CA2813994A1 Compounds, compositions and methods useful for cholesterol mobilisation
04/26/2012CA2813708A1 Arylamide derivatives as ttx-s blockers
04/26/2012CA2813162A1 Pyridine-2- derivatives as smoothened receptor modulators
04/26/2012CA2813063A1 Antagonist for mutated androgen receptor
04/26/2012CA2812891A1 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome
04/26/2012CA2812320A1 Pochoxime conjugates useful for the treatment of hsp90 related pathologies
04/26/2012CA2812187A1 Topical base and active agent-containing compositions, and methods for improving and treating skin
04/26/2012CA2811931A1 Method of treating herpes virus infection using macrocyclic lactone compound
04/26/2012CA2811926A1 Method of treating otitis externa using macrocyclic lactone compound
04/26/2012CA2811924A1 Method of treating hemorrhoids using macrocyclic lactone compound
04/26/2012CA2811171A1 Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
04/25/2012EP2444498A1 Gene therapy for treatment of cancer and hyperproliferative diseases
04/25/2012EP2444482A1 Modulation of SGLT2 expression
04/25/2012EP2444425A1 1:1, 2:1 or 3:1 complex consisting of a cyclodextrin or cyclodextrin derivative and a halogenated ether, production therof and use therof as soporific
04/25/2012EP2444411A1 Tripeptide boronic acid or boronic ester, preparative method and use thereof
04/25/2012EP2444403A1 Heterocyclic compound having inhibitory activity on PI3K
04/25/2012EP2444402A1 Compound having spiro-bonded cyclic group and use thereof
04/25/2012EP2444401A1 Novel imidazopyridine compound
04/25/2012EP2444400A1 Substituted polycyclic carbamoylpyridone derivative
04/25/2012EP2444399A1 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
04/25/2012EP2444398A2 Novel intermediates of voriconazole and preparation method of voriconazole using the same
04/25/2012EP2444397A1 Heteroaryl-ureas and their use as glucokinase activators
04/25/2012EP2444395A1 Substituted isoquinoline derivative
04/25/2012EP2444392A1 (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
04/25/2012EP2444121A1 Use of collismycin and derivatives thereof as oxidative stress inhibitors
04/25/2012EP2444120A1 Spirocyclic amiloride analogues as ENac blockers
04/25/2012EP2444098A1 Traditional chinese medicine composition for treating swine influenza, preparation method and use thereof
04/25/2012EP2444095A1 Rna virus infection inhibitor, method for inhibition of infection by rna virus, products for inhibition of infection by rna virus, and use as rna virus infection inhibitor
04/25/2012EP2444094A1 Mangiferin-berberine salt, manufacturing method and use thereof
04/25/2012EP2444093A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
04/25/2012EP2444092A1 Non-hormonal steroid modulators of nf-kb for treatment of disease
04/25/2012EP2444091A2 Use of toosendanin or melia azedarach extracts for preventing or treating dementia
04/25/2012EP2444090A1 Novel parenteral carbamazepine formulation
04/25/2012EP2444089A2 Anhydrous compositions useful for attaining enhanced sexual wellness
04/25/2012EP2444088A1 Amino derivatives for the treatment of proliferative skin disorders
04/25/2012EP2444087A1 Pharmaceutical composition having improved solubility
04/25/2012EP2444086A1 Combinations comprising DHODH inhibitors and COX inhibitors
04/25/2012EP2444085A1 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
04/25/2012EP2444084A1 Use of PI3K inibitors for the treatment of obesity
04/25/2012EP2444083A1 Cysteine and food intake
04/25/2012EP2444082A2 Hydroxymethylbutyrate compositions and uses thereof
04/25/2012EP2444081A1 A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
04/25/2012EP2444080A2 Stable Pharmaceutical Drug Aerosols
04/25/2012EP2444079A1 Compositions and Methods for Treatment of Eye Disorders
04/25/2012EP2444078A1 Use of amides of mono and dicarboxylic acids in the treatment of renal diseases
04/25/2012EP2444077A1 Pharmaceutical composition for treatment of diabetic complications
04/25/2012EP2444076A1 Fast-dissolving/disintegrating film preparation having high proportion of active agent
1 ... 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 ... 7860